あすか製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証1部 | 医薬品 | 4514/E00929 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2017/02/17 | 日証協 | 210,235株 | -6.58% | 3,856株 | -87.85% | 462,023株 | -0.94% | 18,264株 | -64.23% |
2017/02/10 | 日証協 | 225,053株 | -5.87% | 31,748株 | +12.71% | 466,423株 | +1.02% | 51,064株 | +23.61% |
2017/02/03 | 日証協 | 239,079株 | +5.58% | 28,168株 | +109.33% | 461,721株 | +2.66% | 41,311株 | +67.63% |
2017/01/27 | 日証協 | 226,435株 | -1.86% | 13,456株 | -80.76% | 449,754株 | +1.15% | 24,644株 | +164.14% |
2017/01/20 | 日証協 | 230,735株 | +9.46% | 69,935株 | +883.61% | 444,649株 | -2.86% | 9,330株 | -27.96% |
2017/01/13 | 日証協 | 210,803株 | -6.68% | 7,110株 | -75.54% | 457,762株 | -1.93% | 12,952株 | -33.6% |
2017/01/06 | 日証協 | 225,903株 | -10.3% | 29,069株 | +27.18% | 466,756株 | -4.95% | 19,506株 | -30.83% |
2016/12/30 | 日証協 | 251,835株 | +9.71% | 22,856株 | -40.05% | 491,056株 | +7.55% | 28,200株 | -35.94% |
2016/12/22 | 日証協 | 229,555株 | -11.5% | 38,122株 | -35.89% | 456,571株 | -3.55% | 44,023株 | +9.96% |
2016/12/16 | 日証協 | 259,397株 | +17.54% | 59,460株 | -1.45% | 473,390株 | -2.08% | 40,036株 | -19.63% |
2016/12/09 | 日証協 | 220,679株 | -2.3% | 60,334株 | -22.75% | 483,461株 | -2.7% | 49,816株 | -20.62% |
2016/12/02 | 日証協 | 225,879株 | +3.63% | 78,100株 | +89.15% | 496,861株 | -4.02% | 62,758株 | +7.39% |
2016/11/25 | 日証協 | 217,959株 | -40.01% | 41,289株 | -57.13% | 517,663株 | -21.98% | 58,439株 | -69.73% |
2016/11/18 | 日証協 | 363,341株 | +14.24% | 96,315株 | +3.07% | 663,506株 | +21.35% | 193,089株 | +69.02% |
2016/11/11 | 日証協 | 318,064株 | +23.76% | 93,445株 | +926.87% | 546,774株 | -1.37% | 114,241株 | +78.3% |
2016/11/04 | 日証協 | 257,007株 | -31.71% | 9,100株 | -87.14% | 554,349株 | -9.29% | 64,071株 | -23.44% |
2016/10/28 | 日証協 | 376,339株 | +18.31% | 70,738株 | +144.29% | 611,126株 | +0.28% | 83,690株 | +148.45% |
2016/10/21 | 日証協 | 318,094株 | +8.3% | 28,956株 | -29.08% | 609,415株 | +2.19% | 33,685株 | -41.65% |
2016/10/14 | 日証協 | 293,709株 | +0.99% | 40,830株 | -17.85% | 596,343株 | +4.23% | 57,727株 | -38.28% |
※株式分割は考慮していませんのでご注意ください。
Page Top